There were no surprises from AHP. I think that’s a good trend in general.

I really think what you’ve had here is that they’ve all had the same issue, losing product patents. It’s hard to simply offset that with cost cutting, but it’s nothing systemic in the company.

It’s obviously part of the entire issue of focusing on drug spending and cost and pricing which keeps coming up, but this issue itself is not a major issue.

Pharmacia reported earnings growth of 19 percent, but the pharmaceutical side was up more than 20 percent by itself, so that’s the sustainable long-term piece when they spin off agriculture.